Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials

Author(s):
Kuhnast, S.; Fiocco, M.; Hoorn, J.W.A. van der; Princen, H.M.G.; Jukema, J.W. (0000-0002-3246-8359)
Published
2015
Publication type
Article / Letter to editor
Cardiovascular diseaseClinical outcomeMyocardial infarctionLDL-cholesterolNon-HDL-cholesterolHDL-cholesterolAtherosclerosisClinical trialsAPOE*3Leiden.CETP miceMouseRabbitHamsterNiacinFibratesGlitazonesPPAR agonistsCETP inhibitionSR-BI inhibitorABCA1 degradation inhibitorsReconstituted HDLDelipidated HDLApolipoprotein A-I MilanoApolipoprotein A-I mimeticApolipoprotein A-I inducerLCAT
Date issued
2015-09-15
Language
English
Is part of
European Journal of Pharmacology (2015), Vol. 763, p. 48-63
hdl
1887/108226
doi
10.1016/j.ejphar.2015.03.089